Event Dime
RapidMeta Cardiology: A Browser-Based Living Meta-Analysis Platform Validated Against Finerenone Phase III Trial Data [version 1; peer review: awaiting peer review]
Arts & Culture
- When:
- June 1, 2026 ยท 3:48 AM
- Source:
- F1000Research
Background Living meta-analyses are currently hampered by fragmented software, server dependencies, and limited data provenance. We developed and validated RapidMeta Cardiology, a standalone browser-based meta-analysis platform, using Phase III finerenone trial data as a proof-of-concept benchmark. Methods The application implements DerSimonian-Laird (DL) and REML random-effects meta-analysis for odds ratios (OR), risk ratios (RR), and hazard ratios (HR). Five outcomes (MACE, all-cause mortality